Introduction
============

The female genital tract is rarely involved by metastatic tumors. The most common anatomic locations for metastases to the female genital tract are the ovaries and the vagina. Among extragenital cancers metastasizing to the female genital tract, breast is the most common primary site, followed by the gastrointestinal tract, lung, kidney, and skin (melanoma) ([@b1-ol-0-0-6822],[@b2-ol-0-0-6822]). Metastases to the uterus from extragenital cancer are less common ([@b3-ol-0-0-6822]), but up to 8% of breast carcinomas will metastasize to that organ ([@b4-ol-0-0-6822]). Lobular carcinoma is the most common type of breast carcinoma that metastasizes to the uterus ([@b5-ol-0-0-6822]). When an extragenital tumor metastasizes to the uterus, it is predominantly located in the myometrium; in a minority of cases, the metastasis is confined to the endometrium ([@b1-ol-0-0-6822],[@b2-ol-0-0-6822]). In this article, we present a case of concurrent metastatic breast carcinoma to an endometrial polyp, a uterine leiomyoma, and the uterine cervix. This is the first reported case with this combination. We also review the literature.

Case report
===========

A 58-year-old postmenopausal Japanese woman presented to our gynecological outpatient department with abnormal uterine bleeding in 2015. Nine years previously, she had undergone breast-conserving surgery for cancer of the right breast. Histopathologic examination of that mass revealed a stage IIIc invasive ductal carcinoma in the breast, with large groups of lobular cancer cells and very small groups of ductal cancer cells found in the lymph nodes. After surgery of the breast cancer, the patient had been received adjuvant chemotherapy (doxifluridine 5 years, cyclophosphamide 3 years and docetaxel 1 years) radiotherapy (60 Gy to the right breast) and hormone therapy (goserelin acetate 6 years, tamoxifen 4 months, toremifene citrate 3 years).

A diagnostic work-up was initiated to detect possible causes of vaginal bleeding. She underwent transvaginal ultrasound, which revealed endometrial thickening (9 mm). Magnetic resonance imaging (MRI) revealed a thickened endometrial myometrium (16×32 mm) with multicystic tumors ([Fig. 1](#f1-ol-0-0-6822){ref-type="fig"}). A hysteroscopic examination revealed an endometrial polyp in the uterine cavity, which was resected ([Fig. 2](#f2-ol-0-0-6822){ref-type="fig"}). A pathological examination, including hematoxylin-eosin staining and immunohistochemical staining, was performed ([Fig. 3](#f3-ol-0-0-6822){ref-type="fig"}). The acquisition of tumor tissues of the patients was approved by the Shimane University Institutional Review Board. Hematoxylin and eosin revealed the absence of solid, alveolar, papillary, or gland-forming units. The tumor cells were arranged in slender linear strands, one to two cells in thickness. The tumor cells may have been dispersed in an irregular fashion in a densely fibrotic stroma. Results of immunohistochemical staining for estrogen receptor, progesterone receptor, and HER2 were positive, whereas those for E-cadherin were negative. The morphology, along with the immunohistochemical findings and the clinical history, supported the diagnosis of lobular breast carcinoma metastatic to the endometrial polyp.

A positron emission tomography/computed tomography (PET-CT) examination showed slightly increased uptake in the myoma. The standardized uptake value (SUV) on the PET was 9 in the early phase and 11 in the late phage. Multiple reports suggest that mild or moderate uptake of ^18^F-fludeoxyglucose is often observed in benign uterine leiomyoma and should not be confused with malignant accumulation, and our experience is consistent with this observation. Therefore, the tumor was assumed to be benign, and a laparoscopic hysterectomy was planned. However, because of the large size of the uterus and copious adhesions between the ovary, uterus, and rectum, the procedure was changed to an abdominal hysterectomy. The patient underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, and partial colectomy. Interestingly, the uterine leiomyoma and cervix shared the same histopathologic features as the primary lobular carcinoma of the breast, indicating that metastatic tumor arose from the original breast carcinoma after a 9-year interval. At the time of this report, the patient is alive and receiving aromatase inhibitor therapy.

Discussion
==========

Metastases to the female genital tract from extragenital cancers are less common than metastases from genital tract cancers and most often affect the ovaries, with the breast and gastrointestinal tract being the most common sites of the primary tumor ([@b2-ol-0-0-6822]). The ovaries are often first in the path of spread of malignant cells. They provide an optimal environment for implantation of malignant cells, because they are very vascular with a well-developed lymph network. Additionally, the stroma of ovaries has a favorable pH and oxygen pressure ([@b6-ol-0-0-6822]). On the other hand, the other female genital tract organs, including the uterus, seem resistant to metastasis. Mazur *et al* ([@b1-ol-0-0-6822]) reported that, among 149 metastatic tumors to the female genital tract from extragenital primaries, the ovary and vagina were the most frequent locations of metastases (75.8 and 13.4%, respectively), while only 8.1% were to the uterus (4.7% to the endometrium, 3.4% to the cervix). Breast was the second-most common primary site after gastrointestinal tumors; of 52 breast cancer cases metastatic to the gynecologic organs, ovaries were affected in 88.5% cases, vagina in 5.8%, endometrium in 3.8%, vulva in 1.9% and none to the cervix ([@b1-ol-0-0-6822]).

Metastases to the uterus from extragenital cancers are significantly rarer than metastases to the ovaries. Piura *et al* ([@b7-ol-0-0-6822]) reported 198 cases of extragenital metastases to the uterus, 112 of which originated from primary breast carcinoma. However, reports of breast cancer metastasis to uterine leiomyoma were limited. Leiomyoma of the uterus is the most common benign tumor in women, and it can be found in 20% of women at autopsy ([@b8-ol-0-0-6822]). The low incidence of cancer metastatic to uterine leiomyoma may be explained by the lack of routine autopsy. Kondo *et al* ([@b9-ol-0-0-6822]) described presenting signs and symptoms that may result from metastasis to a uterine leiomyoma in 13 cases, including abnormal bleeding in 6 cases (6/13, 46.2%), enlargement of the uterus in 4 cases, and no symptoms in 3 cases. In view of these observations, abnormal uterine bleeding may be a characteristic of a patient with metastasis to a uterine leiomyoma. Our review of the literature regarding metastasis of a carcinoma to a uterine leiomyoma is summarized in [Table I](#tI-ol-0-0-6822){ref-type="table"}. Reviewing the histological types of breast cancer in these reports, ductal carcinoma comprised 61.55% (8/13) and lobular carcinoma comprised 38.4% (5/13) of metastases to uterine leiomyoma. In our case, the patient was diagnosed with both ductal and lobular breast carcinoma, but only lobular carcinoma metastasized to the uterine leiomyoma, and abnormal uterine bleeding was the first sign of metastasis.

Most extragenital metastases to the cervix arise from primary tumors of the gastrointestinal tract ([@b1-ol-0-0-6822]). Other primary sites include the lung, pancreas, melanoma, urethra, and breast. Breast cancer often metastasizes to the ovary, but rarely to the cervix. Possible explanations for this rarity include the small size of the cervix, its reduced blood flow and distal circulation, and the presence of abundant fibrous tissue, which make the uterine cervix unfavorable for the propagation of malignant cells ([@b10-ol-0-0-6822]). Yazigi *et al* ([@b11-ol-0-0-6822]) summarized the first 24 cases in the literature of breast metastasis to the uterine cervix from his series and previous authors in 1988. Two subsequent cases were reported by Piura *et al* ([@b7-ol-0-0-6822]), and Kennebeck and Alagoz ([@b12-ol-0-0-6822]). Yazigi drew some general conclusions of the patients reviewed. More than two-thirds had vaginal bleeding as a presenting symptom, and greater than 60% had no evidence of disease on examination. Thus, the metastasis would have been missed if complete evaluations had not been performed, including Pap smear, colposcopy, and biopsy. In our case, the patient had irregular vaginal bleeding, and her cervical Pap smear was normal. In most cases, cervical metastasis of breast cancer is a manifestation of widespread disease. In 67--89% of the reported cases, distant metastases of other sites were present at diagnosis of cervical metastasis ([@b12-ol-0-0-6822],[@b13-ol-0-0-6822]). The response of the cervix to metastatic disease is fibrous proliferation and an inflammatory cellular reaction, which may explain the clinical finding of an expanded, indurated cervix ([@b2-ol-0-0-6822]). After reviewing the literature, 8 cases (including our case) of metastatic breast carcinoma to the cervix are presented in [Table II](#tII-ol-0-0-6822){ref-type="table"}. Of these 8 cases, 3 (37.5%) had ductal carcinoma and 5 (62.5%) had lobular carcinoma.

Endometrial metastasis from a breast cancer is also uncommon. Kumar and Hart ([@b2-ol-0-0-6822]) found 2 of 63 cases (3.8%) and Mazur *et al* ([@b1-ol-0-0-6822]) found 7 of 149 cases (4.7%) with metastases to the endometrium. Polyps are the most common benign lesion in the endometrium, and metastasis to a polyp is exceptional. Abrams *et al* ([@b4-ol-0-0-6822]) described 15 cases of breast cancer metastatic to endometrial polyps. Of them, 7 patients had lobular breast cancer, 7 had ductal adenocarcinoma, and 1 had an apocrine type. Ductal carcinoma accounts for approximately 70--75% of all breast cancers, while lobular carcinoma only accounts for 5--20%. Despite its lower incidence among breast cancers, lobular carcinoma is the most frequent histologic type that metastasizes to the female genital tract, being found in more than 80% of all cases. In our case, the patient was diagnosed invasive ductal carcinoma in the breast; lobular and ductal carcinoma both were found together in the lymph node, but histological examination of the endometrial polyp identified only metastatic lobular carcinoma. Thus, our study supports the observation that the metastatic potential of lobular carcinoma for gynecologic organs is higher than that of ductal carcinoma. After analyzing 261 cases of breast cancer, Lamovec and Bracko concluded that lobular carcinoma spreads more frequently to gynecologic organs than ductal carcinoma does ([@b15-ol-0-0-6822]). This may be explained by the more frequent loss of the adhesive molecule E-cadherin in lobular carcinoma. We believe that a similar phenomenon might have taken place in our patient. A summary of all reported cases to date with metastatic carcinoma to an endometrial polyp is presented in [Table III](#tIII-ol-0-0-6822){ref-type="table"}.

Uterine metastases from extragenital cancers are significantly rarer than metastases to the ovary, and when they occur, they are usually secondary to lymphatic spread from preceding ovarian metastases. Metastases restricted to the uterus, without involvement of the ovaries, are indeed very rare and can be explained by hematogenous spread.

In our case, lobular breast carcinoma metastasized to a uterine leiomyoma, the cervix, and an endometrial polyp concurrently, which is exceedingly rare. Although the ovary and vagina are the most common locations of metastasis, the entire organ system is at risk for metastatic disease. Therefore, abnormal uterine bleeding in patients with a history of breast carcinoma should always alert the physician to consider the diagnosis of metastatic spread to the genital tract. Gynecologists who are planning a laparoscopic operation for the patient with a history of lobular breast cancer should consider abdominal dissection rather than laparoscopy, even if the tumor is thought to be benign. If lobular carcinoma remains dormant in the myoma or other gynecological organs, as our case, and the surgeon misses any tissue during the operation, residual disease may spread elsewhere in the peritoneal cavity. Before surgery, the use of PET-CT may be beneficial for identifying an unanticipated mass.

![Magnetic resonance imaging of the pelvis. T2-weighted imaging revealed thickened endometrial myometrium (16×32 mm) with multicystic tumors.](ol-14-04-4585-g00){#f1-ol-0-0-6822}

![Polyp-like tumor in the uterine cavity. The surface of the polyp is smooth.](ol-14-04-4585-g01){#f2-ol-0-0-6822}

![Pathological examination. (A) microscopic image of ductal carcinoma of the right breast. (B) Immunohistochemical staining positive for E-cadherin of ductal carcinoma. (C) Microscopic image of lobular carcinoma of the lymph node. (D) Immunohistochemical staining negative for E-cadherin of lobular carcinoma of lymph node. (E) Metastatic tumor cells from breast lobular carcinoma of leiomyoma, cervix and an endometrial polyp (hematoxylin and eosin). (F) Immunohistochemical staining negative for E-cadherine of uterus.](ol-14-04-4585-g02){#f3-ol-0-0-6822}

###### 

Cases of resected breast cancer metastases to uterine leiomyoma.

  Case no.   Author\'s           Primary histology              Residual metastasis   Hormonal receptor       Postoperative therapy   Prognosis          (Refs.)
  ---------- ------------------- ------------------------------ --------------------- ----------------------- ----------------------- ------------------ ----------------------
    1        Di Bonito *et al*   Lobular carcinoma              Ovary and bone        Unknown                 Unknown                 Died, 5 months     ([@b5-ol-0-0-6822])
    2        Sugiyama *et al*    Ductal carcinoma               AxLN and bone         Unknown                 Unknown                 Died, 14 months    ([@b8-ol-0-0-6822])
    3        Charvolin *et al*   Ductal carcinoma               Nil                   ER(+), PR(−)            C and E                 Alive, 2 years     ([@b16-ol-0-0-6822])
    4        Uner *et al*        Ductal carcinoma               AxLN and bone         ER(+), PR(−)            Unknown                 Died, 4 months     ([@b17-ol-0-0-6822])
    5        Liebmann *et al*    Lobular carcinoma              Unknown               Unknown                 Unknown                 Unknown            ([@b18-ol-0-0-6822])
    6        Minelli *et al*     Ductal carcinoma               Bone and brain        ER(+), PR(+)            C and R                 Died, 1 year       ([@b19-ol-0-0-6822])
    7        Afriat *et al*      Lobular carcinoma              AxLN                  Unknown                 C and E                 Alive, 4 years     ([@b20-ol-0-0-6822])
    8        Beattie *et al*     Ductal carcinoma               AxLN and bone         Unknown                 C                       Unknown            ([@b21-ol-0-0-6822])
    9        Spiro               Ductal carcinoma               AxLN and pleura       Unknown                 Unknown                 Unknown            ([@b22-ol-0-0-6822])
  10         Spiro               Lobular carcinoma              Liver                 Unknown                 C                       Died, 1 year       ([@b22-ol-0-0-6822])
  11         Banooni *et al*     Lobular carcinoma              AxLN and bone         Unknown                 None                    Unknown            ([@b23-ol-0-0-6822])
  12         Birdsall *et al*    Ductal carcinoma               AxLN                  Unknown                 None                    Alive, 10 months   ([@b24-ol-0-0-6822])
  13         Weingold *et al*    Ductal carcinoma               Bone                  Unknown                 Unknown                 Unknown            ([@b25-ol-0-0-6822])
  14         Current case        Ductal and lobular carcinoma   lymph node            ER(+), PR(+) HER2(2+)   C, R, and E             Alive              

ER, estrogen receptor; PR, progesterone receptor; AxLN, indicates axillary lymph nodes; C, chemotherapy; E, endocrine therapy; R, radiation therapy.

###### 

Reported cases of breast cancer with synchronous metastasis to the uterine cervix.

  Case no.   Author\'s          Patient no.   Age (yr)   Clinical presentation   Pap   Initial impression   Primary histology              Treatment                                                 Survival          (Refs.)
  ---------- ------------------ ------------- ---------- ----------------------- ----- -------------------- ------------------------------ --------------------------------------------------------- ----------------- ----------------------
  1          Hepp *et al*       1             55         Abdominal pain          NP    Cervical tumor       Lobular carcinoma              Mastectomy chemotherapy loop excision of cervical tumor   NM                ([@b13-ol-0-0-6822])
  2          Song               2             45         AVB                     \+    Cervical cancer      Ductal carcinoma               Radiation                                                 AAR (6 months)    ([@b26-ol-0-0-6822])
                                3             49         AVB                     −     Cervical cancer      Ductal carcinoma               None                                                      AAR (4 months)    
  3          Limoine *et al*    4             39         AVB                     NP    Cervical cancer      Ductal carcinoma               NM                                                        6 months          ([@b27-ol-0-0-6822])
  4          Fiorella *et al*   5             54         AVB                     \+    Endometrial cancer   Signet ring cell               None                                                      6 months          ([@b28-ol-0-0-6822])
  5          Bogliolo *et al*   6             78         none                    −     Cervical cancer      Lobular carcinoma              Quadrantectomy radiation (breast) chemotherapy            AAR (2.5 years)   ([@b29-ol-0-0-6822])
  6          D\'souza *et al*   7             44         AVB                     \+    Cervical cancer      Lobular carcinoma              NM                                                        NM                ([@b30-ol-0-0-6822])
  7          Horikawa *et al*   8             52         Abdominal discomfort    −     Leiomyoma            Lobular carcinoma              Hysterectomy mastectomy chemotherapy                      AAR (7 years)     ([@b31-ol-0-0-6822])
  8          Current case       9             58         AVB                     −     Endometrial polyp    Ductal and lobular carcinoma   Radiation chemotherapy hormone therapy                    Alive             

Pap, Pap smear; NP, not performed; AAR, alive at time of report; AVB, abnormal vaginal bleeding.

###### 

Summary of reported cases of breast cancer metastases to endometrial polyp.

  Case no.   Author\'s           Age   Histologic type primary tumor   Lymph node metastasis   Clinical symptom   Maximal diameter polyp (cm)   Treatment procedure   (Refs.)
  ---------- ------------------- ----- ------------------------------- ----------------------- ------------------ ----------------------------- --------------------- ----------------------
    1        Kennebeck *et al*   71    Ductal                          Yes                     No                 NM                            Palliative RT/CT      ([@b12-ol-0-0-6822])
    2        Hooker *et al*      83    Lobular                         Yes                     Vaginal bleeding   3.5                           Polyp resection       ([@b14-ol-0-0-6822])
    3        Sullivan *et al*    83    Ductal                          Yes                     No                 11.5                          TAH+BSO               ([@b32-ol-0-0-6822])
    4        Corley *et al*      58    Ductal                          Yes                     Vaginal bleeding   NM                            TAH+BSO               ([@b33-ol-0-0-6822])
    5        Aranda *et al*      76    Lobular                         No                      No                 9                             TAH+BSO               ([@b34-ol-0-0-6822])
    6        Martinez *et al*    78    Lobular                         Yes                     Vaginal bleeding   3.3                           TAH+BSO               ([@b35-ol-0-0-6822])
    7        Martinez *et al*    58    Ductal                          Yes                     Vaginal bleeding   NM                            TAH+BSO               ([@b35-ol-0-0-6822])
    8        Lambot *et al*      70    Apocrine                        Yes                     Vaginal bleeding   1.5                           TAH+BSO               ([@b36-ol-0-0-6822])
    9        Horn *et al*        73    Ductal                          No                      No                 8                             TAH+BSO               ([@b37-ol-0-0-6822])
  10         Alvarez *et al*     69    Lobular                         Yes                     Vaginal bleeding   1.5                           None d                ([@b38-ol-0-0-6822])
  11         Houghton *et al*    62    Lobular                         Yes                     Vaginal bleeding   3                             Polyp resection       ([@b39-ol-0-0-6822])
  12         Houghton *et al*    92    Lobular                         Unknown                 Vaginal bleeding   3                             Polyp resection       ([@b39-ol-0-0-6822])
  13         Al-brahim *et al*   53    Lobular                         Yes                     Vaginal bleeding   7                             Polyp resection       ([@b40-ol-0-0-6822])
  14         Acikalin *et al*    58    Ductal                          Yes                     No                 5                             TAH+BSO               ([@b41-ol-0-0-6822])
  15         Manipadam *et al*   70    Lobular                         Yes                     Vaginal bleeding   3                             Polyp resection       ([@b42-ol-0-0-6822])
  16         Aydin *et al*       60    Ductal                          Unknown                 Vaginal bleeding   6.5                           CT, ANA               ([@b43-ol-0-0-6822])
  17         Current case        58    Ductal and lobular              Yes                     Vaginal bleeding   3.2                           Polyp resection       

BSO, bilateral salpingo-oophorectomy; RT, radiotherapy; CT, chemotherapy; ANA, anastrozole; NM, not mentioned; TAH, total abdominal hysterectomy.
